Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model

被引:0
|
作者
Jinghua Qin
Xue Ling
Qianyi Wang
Zheng Huang
Bingjian Guo
Chi Zhang
Mingwei Meng
Shisui Feng
Yue Guo
Hua Zheng
Yonghong Liang
Zhiheng Su
机构
[1] Guangxi Medical University,Pharmaceutical College
[2] Guangxi Institute of Traditional Medical and Pharmaceutical Sciences,Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards
[3] Life Sciences Institute,undefined
[4] Guangxi Medical University,undefined
[5] Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation,undefined
[6] Guangxi Engineering Research Center for Beibu Gulf Marine Biomedicine Precision Development and High-Value Utilization,undefined
[7] Guangxi Health Commission Key Laboratory of Basic Research On Antigeriatric Drugs,undefined
来源
关键词
T2DM with NAFLD; 16S rRNA gene sequencing; Gut microbiota; Metabolomics; Metabolites;
D O I
暂无
中图分类号
学科分类号
摘要
Globally 80% type 2 diabetes mellitus (T2DM) patients suffer nonalcoholic fatty liver disease (NAFLD). The interplay of gut microbiota and endogenous metabolic networks has not yet been reported in the setting of T2DM with NAFLD. As such, this study utilized 16S rRNA gene sequencing to assess the changes in intestinal flora and nuclear magnetic resonance spectroscopy (1H NMR) to identify potential metabolites in a T2DM with NAFLD rat model. Spearman correlation analysis was performed to explore the relationship between gut microbiota and metabolites. Results revealed that among T2DM with NAFLD rats, diversity indexes of intestinal microbiota were distinctly decreased while levels of 18 bacterial genera within the intestinal tract were significantly altered. In addition, levels of eight metabolites mainly involved in the synthesis and degradation of ketone bodies, the TCA cycle, and butanoate metabolism were altered. Correlation analysis revealed that gut bacteria such as Blautia, Ruminococcus torques group, Allobaculum, and Lachnoclostridium strongly associate with 3-hydroxybutyrate, acetone, acetoacetate, 2-oxoglutarate, citrate, creatinine, hippurate, and allantoin. Our findings can provide a basis for future development of targeted treatments.
引用
收藏
页码:6478 / 6494
页数:16
相关论文
共 50 条
  • [1] Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model
    Qin, Jinghua
    Ling, Xue
    Wang, Qianyi
    Huang, Zheng
    Guo, Bingjian
    Zhang, Chi
    Meng, Mingwei
    Feng, Shisui
    Guo, Yue
    Zheng, Hua
    Liang, Yonghong
    Su, Zhiheng
    [J]. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2023, 195 (11) : 6478 - 6494
  • [2] Gut microbial metabolites in obesity, NAFLD and T2DM
    Emanuel E. Canfora
    Ruth C. R. Meex
    Koen Venema
    Ellen E. Blaak
    [J]. Nature Reviews Endocrinology, 2019, 15 : 261 - 273
  • [3] Gut microbial metabolites in obesity, NAFLD and T2DM
    Canfora, Emanuel E.
    Meex, Ruth C. R.
    Venema, Koen
    Blaak, Ellen E.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) : 261 - 273
  • [4] The synchronized feature of Saururus chinensis and gut microbiota against T2DM, NAFLD, obesity and hypertension via integrated pharmacology
    Oh, Ki-Kwang
    Yoon, Sang-Jun
    Song, Seol Hee
    Park, Jeong Ha
    Kim, Jeong Su
    Kim, Dong Joon
    Suk, Ki-Tae
    [J]. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2024, 52 (01) : 278 - 290
  • [5] Gut microbiota: A new target for T2DM prevention and treatment
    Liu, Lulu
    Zhang, Jiheng
    Cheng, Yi
    Zhu, Meng
    Xiao, Zhifeng
    Ruan, Guangcong
    Wei, Yanling
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [6] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    A. L. Cunningham
    J. W. Stephens
    D. A. Harris
    [J]. Gut Pathogens, 13
  • [7] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    Cunningham, A. L.
    Stephens, J. W.
    Harris, D. A.
    [J]. GUT PATHOGENS, 2021, 13 (01)
  • [8] Microbial metabolite linked to T2DM
    Morris, Alan
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2018, 15 (01) : 3 - 3
  • [9] Microbial metabolite linked to T2DM
    Alan Morris
    [J]. Nature Reviews Endocrinology, 2019, 15 : 3 - 3
  • [10] NAFLD prevalence in older patients with T2DM
    Kotsiliti, Eleni
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65